1. Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. (22nd June 2009) Authors: Giovannini, Monica; Gregorc, Vanesa; Belli, Carmen; Roca, Elisa; Lazzari, Chiara; Viganò, Maria Grazia; Serafico, Anna; Villa, Eugenio Other Names: Mehta Minesh Academic Editor. Journal: Journal of oncology Issue: Volume 2009(2009) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. (22nd June 2009) Authors: Giovannini, Monica; Gregorc, Vanesa; Belli, Carmen; Roca, Elisa; Lazzari, Chiara; Viganò, Maria Grazia; Serafico, Anna; Villa, Eugenio Other Names: Mehta Minesh Academic Editor. Journal: Journal of oncology Issue: Volume 2009(2009) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. CMET-22. CAPMATINIB (INC280) IN METΔEX14-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY DATA FROM THE PHASE 2 GEOMETRY MONO-1 STUDY. (11th November 2019) Authors: Heist, Rebecca S; Seto, Takashi; Han, Ji-Youn; Reguart, Noemi; Garon, Edward B; Groen, Harry J M; Tan, Daniel S W; Hida, Toyoaki; de Jonge, Maja; V Orlov, Sergey; Smit, Egbert F; Souquet, Pierre-Jean; Vansteenkiste, Johan; Le Mouhaer, Sylvie; Robeva, Anna; Waldron-Lynch, Maeve; Giovannini, Monica... Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2‐drug cocktail in patients with MET‐dysregulated advanced solid tumours: A phase I, multicentre, open‐label, single‐sequence drug–drug interaction study. Issue 7 (29th December 2020) Authors: Grande, Enrique; Giovannini, Monica; Marriere, Eddie; Pultar, Philippe; Quinlan, Michelle; Chen, Xinhui; Rahmanzadeh, Gholamreza; Curigliano, Giuseppe; Cui, Xiaoming Journal: British journal of clinical pharmacology Issue: Volume 87:Issue 7(2021) Page Start: 2867 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET‐dysregulated solid tumours. Issue 3 (17th October 2022) Authors: Chen, Xinhui; Isambert, Nicolas; López‐López, Rafael; Giovannini, Monica; Pognan, Nathalie; Kapoor, Shruti; Quinlan, Michelle; You, Benoit; Cui, Xiaoming; Rahmanzadeh, Gholamreza; Mau‐Sorensen, Morten Journal: British journal of clinical pharmacology Issue: Volume 89:Issue 3(2023) Page Start: 1046 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects. (2nd November 2022) Authors: Cui, Xiaoming; Chen, Xinhui; Pognan, Nathalie; Sengupta, Tirtha; Rahmanzadeh, Gholamreza; Kornberger, Ruediger; Giovannini, Monica Journal: Journal of clinical pharmacology Issue: Volume 63:Number 2(2023) Page Start: 228 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF. (3rd June 2010) Authors: Corti, Angelo; Giovannini, Monica; Belli, Carmen; Villa, Eugenio Other Names: Dudek Arkadiusz Academic Editor. Journal: Journal of oncology Issue: Volume 2010(2010) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Nazartinib for treatment-naive EGFR-mutant non−small cell lung cancer: Results of a phase 2, single-arm, open-label study. (September 2022) Authors: Tan, Daniel S.W.; Kim, Sang-We; Ponce Aix, Santiago; Sequist, Lecia V.; Smit, Egbert F.; Yang, James C.H.; Hida, Toyoaki; Toyozawa, Ryo; Felip, Enriqueta; Wolf, Juergen; Grohé, Christian; Leighl, Natasha B.; Riely, Gregory; Cui, Xiaoming; Zou, Mike; Ghebremariam, Samson; O'Sullivan-Djentuh, Lesli... Journal: European journal of cancer Issue: Volume 172(2022) Page Start: 276 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Pharmacokinetics of capmatinib in participants with hepatic impairment: A phase 1, open‐label, single‐dose, parallel‐group study. Issue 1 (18th June 2021) Authors: Chen, Xinhui; Cui, Xiaoming; Pognan, Nathalie; Quinlan, Michelle; Kapoor, Shruti; Rahmanzadeh, Gholamreza; Giovannini, Monica; Marbury, Thomas C. Other Names: Magavern Emma guestEditor.; Piasecki Jan guestEditor.; Cremers Serge guestEditor.; Cohen Adam guestEditor. Journal: British journal of clinical pharmacology Issue: Volume 88:Issue 1(2022) Page Start: 91 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts. Issue 2 (30th December 2019) Authors: Bang, Yung‐Jue; Su, Wu‐Chou; Schuler, Martin; Nam, Do‐Hyun; Lim, Wan Teck; Bauer, Todd M.; Azaro, Analia; Poon, Ronnie Tung Ping; Hong, David; Lin, Chia‐Chi; Akimov, Mikhail; Ghebremariam, Samson; Zhao, Sylvia; Giovannini, Monica; Ma, Brigette Journal: Cancer science Issue: Volume 111:Issue 2(2020) Page Start: 536 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗